Go Pro

Olivia Brayer Saunders Analyst Performance

Analyst at Cantor Fitzgerald

Olivia Brayer Saunders is a stock analyst at Cantor Fitzgerald focused in the medical sector, covering 4 publicly traded companies. Over the past year, Olivia Brayer Saunders has issued 5 stock ratings, including and buy recommendations. While full access to Olivia Brayer Saunders' proprietary MarketBeat Analyst Ranking is reserved for MarketBeat All Access subscribers, the rating is updated daily to reflect the most recent analyst activity. This profile highlights Olivia Brayer Saunders' coverage history, rating activity, and performance tendencies - helping individual investors make more informed trading decisions.

Analyst Rankings, Coverage, and Performance Statistics

Average Return
00.00% 12-Month ROI
Success Rate
00.00% Profitable Ratings
Total Ratings
5 Last 0 Years
Buy Recommendations
100.00% 5 Buy Ratings
Companies Covered
4 Unique Companies

Ratings Distribution

RatingPercentageCount
Strong Buy0.0%0 ratings
Buy100.0%5 ratings
Hold0.0%0 ratings
Sell0.0%0 ratings

the majority (100.0%) have been Buy recommendations.

Best & Worst Calls

This analyst does not have any ratings with enough history to determine best and worst calls.

Exchange Coverage

ExchangePercentageCount
NASDAQ
75.0% of companies on NASDAQ
3 companies
NYSEAMERICAN
25.0% of companies on NYSEAMERICAN
1 company

Olivia Brayer Saunders, an analyst at Cantor Fitzgerald, currently covers 4 companies listed on NASDAQ and NYSEAMERICAN, with the majority traded on NASDAQ.

Coverage Focus

Sector IconSectorPercentage
Medical
3 companies
75.0%
Manufacturing
1 company
25.0%

Olivia Brayer Saunders of Cantor Fitzgerald specializes in stock coverage within the Medical sector, with additional focus on Manufacturing companies.

Coverage Industries

IndustryPercentage
MED - BIOMED/GENE
2 companies
50.0%
BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES
1 company
25.0%
MED - DRUGS
1 company
25.0%

Olivia Brayer Saunders' Ratings History at Cantor Fitzgerald

Recommendation ROI is the percentage between the price on the Report Date to the price 12 months after the report date.
Available with a MarketBeat All Access Subscription
12-Month ROIUpgrade to All Access to use the All ROI Filter
CompanyReport DateActionReport Date Price12-Month
Price Target
Rating12-Month
Price & ROI
Details
Tenax Therapeutics, Inc. stock logo
TENX
Tenax Therapeutics
7/29/2026Reiterated Rating$15.80$35.00Overweight
Quince Therapeutics, Inc. stock logo
QNCX
Quince Therapeutics
6/23/2026Initiated Coverage$18.55$80.00Overweight
Pelthos Therapeutics Inc. stock logo
PTHS
Pelthos Therapeutics
4/1/2026Initiated Coverage$21.01$50.00Overweight
Tenax Therapeutics, Inc. stock logo
TENX
Tenax Therapeutics
3/17/2026Initiated Coverage$13.98$35.00Overweight
United Therapeutics Corporation stock logo
UTHR
United Therapeutics
3/12/2026Boost Price Target$535.20$625.00Overweight